FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition containing 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrol-3-carboxamide referred to in this application as a 'Compound A', or a pharmaceutically acceptable salt thereof, and a cyclodextrin. More specifically, the invention relates to a solid pharmaceutical composition containing Compound A and a cyclodextrin and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. In addition, the invention relates to the use of such compositions for the treatment of malignancy.
EFFECT: obtaining a composition of bcl-2 inhibitor based on cyclodextrin.
31 cl, 9 ex, 1 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
| DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
| PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2772939C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
| UREA-BASED COMPOUNDS AND COMPOSITIONS BASED ON THEM AS SMARCA2/BRM ATPASE INHIBITORS | 2019 |
|
RU2798462C2 |
| LYOPHILISED PREPARATION OF CYTOTOXIC DIPEPTIDES | 2012 |
|
RU2597154C2 |
| CRYSTALLINE BROMODOMAIN INHIBITORS | 2014 |
|
RU2675268C2 |
| IMAGING MEANS FOR RADIOLABELED EXOGENOUS AND ENDOGENOUS ALBUMIN | 2019 |
|
RU2819907C2 |
| STABLE COMPOSITIONS OF IMMUNOCONJUGATES CONTAINING ANTIBODIES TO CD79b | 2019 |
|
RU2800803C2 |
